Arcellx, a Phase 1 biotech developing immunotherapies for patients with cancer and other incurable diseases, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
Arcellx's lead ddCAR candidate, CART-ddBCMA, is in Phase 1 development for the treatment of relapsed or refractory (r/r) multiple myeloma (MM). The company believes preliminary results from the trial demonstrate that D-Domains can potentially provide meaningful clinical benefits. Arcellx plans to initiate a Phase 2 pivotal trial of CART-ddBCMA for treatment of r/r MM in late 2022, as well as pursue development of the candidate in earlier lines of therapy.
The Gaithersburg, MD-based company was founded in 2014 and plans to list on the Nasdaq under the symbol ACLX. Arcellx filed confidentially on May 1, 2020. BofA Securities, SVB Leerink, Barclays, and William Blair are the joint bookrunners on the deal. No pricing terms were disclosed.
